Aclaris Therapeutics, Inc. ACRS
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 43.79% | 43.75% | 46.50% | 50.84% | -282.88% |
| Total Depreciation and Amortization | -16.97% | -25.35% | -38.15% | -43.74% | -44.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -88.06% | -87.63% | -85.84% | -85.35% | 1,530.95% |
| Change in Net Operating Assets | -407.00% | -96.58% | -83.43% | -75.54% | -106.18% |
| Cash from Operations | -75.23% | -521.34% | -323.85% | -134.68% | -139.80% |
| Capital Expenditure | -24.14% | -84.38% | -179.31% | 8.26% | 84.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.28% | 105.91% | 97.62% | 169.60% | -287.10% |
| Cash from Investing | 14.21% | 105.72% | 97.50% | 169.32% | -291.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 45.92% | -27.35% | -27.49% | -- | 8,720.29% |
| Repurchase of Common Stock | 19.29% | 30.62% | 33.07% | -9.05% | -711.84% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 70.83% | -6.47% | -6.47% | -6.47% | -884.38% |
| Cash from Financing | 59.80% | -29.63% | -29.77% | -107.86% | 1,424,940.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 78.29% | -342.80% | 69.06% | 69.89% | -360.07% |